article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

Food and Drug Administration (FDA) advisory committees, an analysis of the key patents covering drugs recently approved by the FDA, and an examination of high-risk cardiovascular devices approved by the FDA for use in children and adolescents. Improving the Use of FDA Advisory Committees. N Engl J Med.

article thumbnail

Vendor Notebook: new tools and acquisitions from OptumRx, ScionHealth, others

Healthcare IT News - Telehealth

OptumRx launched Price Edge, a tool that compares pricing for traditional generic drugs to ensure members get the lowest prescription drug prices. FDA is currently reviewing use of Selux's NGP Gram-Negative panel. Inspira Technologies said it received patent approval from the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

Kaiser Health News

“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”

Doctors 88
article thumbnail

New CDC Opioid Guidelines: Too Little, Too Late for Chronic Pain Patients?

Kaiser Health News

“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”

Doctors 52
article thumbnail

Health Provider News – February 18, 2022

Hall Render

Meet new FDA chief Dr. Robert Califf: 5 things to know. Only 14% of Hospitals Met Price Transparency Rule Compliance. Bill on prescription drug pricing inspires support from Maine residents, opposition from pharmaceutical industry. Hospitals urge HHS to fix, not end, direct contracting model.

article thumbnail

The Gap Between the Trump Administration’s Promise of Reducing Rx Costs for Consumers and What People Really Want

Health Populi

This is what happened to pharma stock prices on Friday after President Trump and Secretary of Health and Human Services Alex Azar outlined their new policies focusing on prescription drug prices. The graph is the Nasdaq U.S. Foreign governments’ “free-riding” Americans’ investment in innovation.

article thumbnail

Rx 2018: A New Era of Specialty Drugs, Telehealth, Mobile Apps and Value, IQVIA Reports

Health Populi

Health Populi’s Hot Points: The big wild card in forecasting what prescription drug spending will look like in the U.S. is just how aggressive Dr. Alex Azar at the Department of Health and Human Services, and Dr. Scott Gottlieb at FDA, want to be regarding drug pricing.